An important milestone for Morphsys and I-Mab’s MOR210 / TJ210 antibody project: The US FDA has approved the two companies’s IND application. “The phase 1 clinical trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of MOR210 / TJ210 can begin,” said Morphosys. “The IND approval for the start of a phase 1 clinical trial for MOR210 / TJ210 is an important step in the development of a new treatment for patients with advanced cancer,” said Malte Peters, Chief Research and Development Officer at Morphosys.
The antibody is intended to be tested in the treatment of patients with relapsed or refractory advanced solid tumors. This has shown encouraging results in preclinical studies, says Joan Shen, chief executive officer of I-Mab. The biotech companies report that MOR210 / TJ210 in combination with immune checkpoint inhibitors exerted strong anti-tumor activity.
Morphsys stock is benefiting only marginally from the announcement today. The TecDAX-listed biotech share is currently up 0.22 percent at 115.20 euros.
More about biotech stocks on 4investors: click here
At a glance – chart and news: MorphoSys